Dennis Joseph Slamon (born August 6, 1948), [1][2] is an American oncologist and chief of the division of Hematology-Oncology at UCLA. He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab. Feb 16, 2024 · "It was pretty exhilarating to see that what we had thought about in theory and what we were able to show in models really worked in patients,” Dr. Slamon recalls of his earlier years conducting research to develop the groundbreaking breast cancer drug Herceptin. One of the central figures behind that medical success story is Dennis J. Slamon, MD, PhD, a professor and chief of hematology/oncology at the David Geffen School of Medicine at the University of California at Los Angeles (UCLA). Slamon, M.D., Ph.D., a UCLA oncologist and researcher, transformed breast cancer treatment through his pioneering identification of the HER2/neu oncogene, amplified in roughly a quarter to a third of breast cancers. Nov 25, 2023 · Slamon serves as Director of Clinical/Translational Research and Director of the Revlon/UCLA Women’s Cancer Research Program at Jonsson Comprehensive Cancer Center. Apr 24, 2026 · Slamon is widely recognized for his pioneering work in breast cancer research and treatment, including his groundbreaking discovery of the HER2 gene’s role in aggressive forms of breast... DennisSlamon, a world-renowned oncologist and scientist whose groundbreaking research has transformed the treatment of breast cancer, has been awarded the 2024 Szent-Györgyi Prize for Progress in Cancer Research from the National Foundation for Cancer Research.
